Overview
Shares of Nuwellis Inc (NASDAQ:NUWE) plummeted 65.2% in premarket trading Friday after the company unveiled a public offering priced sharply below recent trading levels. The offering includes 20,000,000 shares of common stock sold together with accompanying warrants at a price of $0.30 per share, which should produce gross proceeds of approximately $6 million if fully subscribed.
Warrant structure and exercise terms
The deal bundles two warrant series. Both Series C and Series D warrants carry an exercise price of $0.30. Under the terms announced, each warrant will be exercisable for a five-year period, but only after stockholder approval and following the effective date of a reverse stock split - a condition stated to be required by Nasdaq rules. The Series C Warrants incorporate a one-time reset provision that is tied to any reverse stock split implemented by the company. The Series D Warrants include a zero cash exercise mechanism, enabling holders to receive shares without submitting additional cash at exercise.
The offering comprises Series C Warrants to purchase up to 60,000,000 shares of common stock and Series D Warrants to purchase up to 20,000,000 shares.
Concurrent private placement and repricing
Alongside the public sale, Nuwellis said it completed warrant reprice transactions in a private placement with certain existing warrant holders. These amendments lower the exercise price of previously issued warrants to $0.30. The company noted the exercise of these repriced warrants will require stockholder approval.
Placement agent and business focus
Ladenburg Thalmann & Co. Inc. acted as exclusive placement agent for the offering. Nuwellis describes itself as a medical technology company focused on solutions for patients with cardiorenal conditions.
What happened in the market
The announcement and the terms of the offering coincided with the steep premarket decline in the company’s share price. The offering price - set at $0.30 per share with attached warrants - was noted as being significantly below recent trading levels, and the company quantified the gross proceeds expected from the public sale at roughly $6 million.